S

SVN001

Product

Heard in 2 episodes across 1 show since Jul 2026

SVN001 is an investigational drug candidate being developed for alcohol use disorder and evaluated in a Phase 3 clinical study.

Episodes

2
across 1 show

First heard

Jul 2026

Expert statements

3
3 positive

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20261
Aug 20261
Sep 20260
Oct 20260
Nov 20260

Email alert

Email me when SVN001 comes up on a podcast

One email a week at most, with the new episodes that mention SVN001. Free, no account needed, unsubscribe in one click.

What experts have said about SVN001

3 statements · 3 positive

  1. David NuttPositiveOct 4, 2026· The Sunday Roast

    SVN-001’s active arm was 50% better than placebo on the trial outcome.

    “the active arm, the 001 arm, was 50% better than the placebo.”

    Listen at 53:06

    Open the episode · S12 Ep6: Sunday Roast - Mantle Resilience Plc,Xtract Resources,Bezant Resources,Solvonis Therapeutics plc, African Pioneer, Kendrick Resources, Active Energy Group PLC, Critical Mineral Resources & Galileo Resources #MNTL #XTR #BZT #SVNS #AFP #KEN #AEG #CMRS #GLR
  2. Anthony TennysonPositiveAug 26, 2026· The Sunday Roast

    EU trial data could improve SVN001’s probability of EU marketing approval.

    “what our hope would be that if we have EU data in the trial, it would increase the probability of an accepted marketing authorization or marketing approval in certain EU countries in due course.”

    Listen at 3:59

    Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
  3. Anthony TennysonPositiveAug 26, 2026· The Sunday Roast

    Adding EU data would significantly increase SVN001’s strategic optionality.

    “by potentially adding in EU data, we increase the, let's just call it optionality for that program, I believe, significantly.”

    Listen at 6:38

    Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

2 episodes featuring SVN001, newest first